The exosome diagnostic and therapeutic market size has grown exponentially in recent years. It will grow from $0.6 billion in 2025 to $0.77 billion in 2026 at a compound annual growth rate (CAGR) of 28%. The growth in the historic period can be attributed to advancements in molecular biology research, rising investment in regenerative medicine, increasing academic research on extracellular vesicles, expansion of biotech research infrastructure, growing availability of exosome analysis tools.
The exosome diagnostic and therapeutic market size is expected to see exponential growth in the next few years. It will grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 28%. The growth in the forecast period can be attributed to increasing clinical translation of exosome therapies, rising demand for personalized medicine solutions, expansion of ai-enabled exosome data analysis, growing pharmaceutical interest in biologic delivery systems, increasing regulatory clarity for advanced therapies. Major trends in the forecast period include increasing use of exosomes for targeted drug delivery, rising adoption of liquid biopsy diagnostics, growing demand for regenerative medicine applications, expansion of advanced exosome isolation technologies, enhanced focus on precision therapeutic development.
The anticipated growth of the exosome diagnostic and therapeutic market is strongly driven by the increasing prevalence of chronic diseases. Chronic illnesses, lasting three months or more and prone to deterioration over time, are a significant health concern globally. Exosomes, utilized in both diagnostic and therapeutic capacities, emerge as promising biomarkers in cancer, enabling more sensitive disease monitoring and facilitating the accessibility of personalized medicine. In a projection from January 2023, the National Center for Biotechnology Information (NCBI) indicates a forecasted global count of 142.66 million individuals with chronic diseases by 2050. This statistic underscores the pivotal role played by the rising prevalence of chronic diseases in propelling the exosome diagnostics and therapeutics market.
Major companies are actively engaged in developing innovative products, such as sample purification systems, to expand their customer base, boost sales, and drive revenue growth. A sample purification system encompasses a suite of processes and technologies designed to eliminate impurities and contaminants from various sample types, including DNA, RNA, proteins, and other biomolecules. As an illustration, in February 2023, Biological Dynamics Inc., a prominent US-based biotechnology company, introduced ExoVerita - an exosome-isolation platform designed for early disease surveillance and diverse applications. The ExoVita Pancreas assay, part of this platform, identifies specific exosomal protein indicators and has demonstrated the ability to detect Stage 1 and Stage 2 pancreatic ductal adenocarcinoma (PDAC) using blood-based exosome samples enriched on the patented ExoVerita apparatus. The company is actively validating these findings through the ExoLuminate registry trial (NCT05625529), recruiting high-risk PDAC patients to assess the clinical value of the test.
In June 2023, Evox Therapeutics Ltd., a biotechnology company based in the UK, acquired the engEx-AAV technology platform from Codiak Biosciences for an undisclosed sum. The purpose of this acquisition is to utilize the engEx-AAV technology to improve exosome-mediated delivery systems, facilitating the advancement of innovative gene therapies and genome editors. This strategic decision aims to bolster Evox Therapeutics' capabilities in developing effective genetic medicines. Codiak Biosciences is a biopharmaceutical company located in the US that focuses on creating exosome-based therapeutics.
Major companies operating in the exosome diagnostic and therapeutic market are Thermo Fisher Scientific Inc., Miltenyi Biotec GmbH, Malvern Instruments Inc., System Biosciences LLC, NanoSomix Inc., Exosome Diagnostics Inc., Evox Therapeutics Ltd., ExCoBio Inc., Codiak BioSciences Inc., Capricor Therapeutics Inc., Aethlon Medical Inc., NX Pharmagen Inc., Aegle Therapeutic Corporation, Ciloa, Sistemic Inc., Theoria Science, Mantra Bio Inc., Lonza Group AG, Bio-Techne Corp.
North America was the largest region in the exosome diagnostic and therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exosome diagnostic and therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the exosome diagnostic and therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the exosome diagnostic and therapeutic market by increasing costs of imported analytical instruments, isolation systems, reagents, consumables, and laboratory automation equipment. Research institutes and biotechnology companies in North America and Europe are most affected due to dependence on specialized imported tools, while Asia-Pacific faces cost pressures on manufacturing and export of research-grade systems. These tariffs are increasing research and development expenditure and slowing procurement timelines. However, they are also supporting local manufacturing of laboratory equipment, regional reagent production, and domestic innovation ecosystems for advanced biologics research.
The exosome diagnostic and therapeutic market research report is one of a series of new reports that provides exosome diagnostic and therapeutic market statistics, including exosome diagnostic and therapeutic industry global market size, regional shares, competitors with a exosome diagnostic and therapeutic market share, detailed exosome diagnostic and therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the exosome diagnostic and therapeutic industry. This exosome diagnostic and therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Exosome diagnostics and therapeutics involve utilizing exosomes - small extracellular particles produced by cells - for both diagnostic and therapeutic purposes. Exosomes are employed in therapeutic applications as a means of delivering targeted medications, particularly within the field of regenerative medicine.
The primary products within the exosome diagnostic and therapeutic market comprise instruments, software, reagents, and kits. Instruments refer to equipment utilized for precise and accurate execution of activities or experiments. These products find diverse applications in diagnostics and therapeutics and cater to various end-users, including academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, among others.
The exosome diagnostic and therapeutic market consists of revenues earned by entities by providing services such as genomic sequencing, exome sequencing, resequencing, and targeted sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. The exosome diagnostic and therapeutic market also includes sales of exosome-based assays, exosome flow cytometry kits, and protein biomarker detection kits, which are used in providing exosome-based drug delivery services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The exosome diagnostic and therapeutic market size is expected to see exponential growth in the next few years. It will grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 28%. The growth in the forecast period can be attributed to increasing clinical translation of exosome therapies, rising demand for personalized medicine solutions, expansion of ai-enabled exosome data analysis, growing pharmaceutical interest in biologic delivery systems, increasing regulatory clarity for advanced therapies. Major trends in the forecast period include increasing use of exosomes for targeted drug delivery, rising adoption of liquid biopsy diagnostics, growing demand for regenerative medicine applications, expansion of advanced exosome isolation technologies, enhanced focus on precision therapeutic development.
The anticipated growth of the exosome diagnostic and therapeutic market is strongly driven by the increasing prevalence of chronic diseases. Chronic illnesses, lasting three months or more and prone to deterioration over time, are a significant health concern globally. Exosomes, utilized in both diagnostic and therapeutic capacities, emerge as promising biomarkers in cancer, enabling more sensitive disease monitoring and facilitating the accessibility of personalized medicine. In a projection from January 2023, the National Center for Biotechnology Information (NCBI) indicates a forecasted global count of 142.66 million individuals with chronic diseases by 2050. This statistic underscores the pivotal role played by the rising prevalence of chronic diseases in propelling the exosome diagnostics and therapeutics market.
Major companies are actively engaged in developing innovative products, such as sample purification systems, to expand their customer base, boost sales, and drive revenue growth. A sample purification system encompasses a suite of processes and technologies designed to eliminate impurities and contaminants from various sample types, including DNA, RNA, proteins, and other biomolecules. As an illustration, in February 2023, Biological Dynamics Inc., a prominent US-based biotechnology company, introduced ExoVerita - an exosome-isolation platform designed for early disease surveillance and diverse applications. The ExoVita Pancreas assay, part of this platform, identifies specific exosomal protein indicators and has demonstrated the ability to detect Stage 1 and Stage 2 pancreatic ductal adenocarcinoma (PDAC) using blood-based exosome samples enriched on the patented ExoVerita apparatus. The company is actively validating these findings through the ExoLuminate registry trial (NCT05625529), recruiting high-risk PDAC patients to assess the clinical value of the test.
In June 2023, Evox Therapeutics Ltd., a biotechnology company based in the UK, acquired the engEx-AAV technology platform from Codiak Biosciences for an undisclosed sum. The purpose of this acquisition is to utilize the engEx-AAV technology to improve exosome-mediated delivery systems, facilitating the advancement of innovative gene therapies and genome editors. This strategic decision aims to bolster Evox Therapeutics' capabilities in developing effective genetic medicines. Codiak Biosciences is a biopharmaceutical company located in the US that focuses on creating exosome-based therapeutics.
Major companies operating in the exosome diagnostic and therapeutic market are Thermo Fisher Scientific Inc., Miltenyi Biotec GmbH, Malvern Instruments Inc., System Biosciences LLC, NanoSomix Inc., Exosome Diagnostics Inc., Evox Therapeutics Ltd., ExCoBio Inc., Codiak BioSciences Inc., Capricor Therapeutics Inc., Aethlon Medical Inc., NX Pharmagen Inc., Aegle Therapeutic Corporation, Ciloa, Sistemic Inc., Theoria Science, Mantra Bio Inc., Lonza Group AG, Bio-Techne Corp.
North America was the largest region in the exosome diagnostic and therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exosome diagnostic and therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the exosome diagnostic and therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the exosome diagnostic and therapeutic market by increasing costs of imported analytical instruments, isolation systems, reagents, consumables, and laboratory automation equipment. Research institutes and biotechnology companies in North America and Europe are most affected due to dependence on specialized imported tools, while Asia-Pacific faces cost pressures on manufacturing and export of research-grade systems. These tariffs are increasing research and development expenditure and slowing procurement timelines. However, they are also supporting local manufacturing of laboratory equipment, regional reagent production, and domestic innovation ecosystems for advanced biologics research.
The exosome diagnostic and therapeutic market research report is one of a series of new reports that provides exosome diagnostic and therapeutic market statistics, including exosome diagnostic and therapeutic industry global market size, regional shares, competitors with a exosome diagnostic and therapeutic market share, detailed exosome diagnostic and therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the exosome diagnostic and therapeutic industry. This exosome diagnostic and therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Exosome diagnostics and therapeutics involve utilizing exosomes - small extracellular particles produced by cells - for both diagnostic and therapeutic purposes. Exosomes are employed in therapeutic applications as a means of delivering targeted medications, particularly within the field of regenerative medicine.
The primary products within the exosome diagnostic and therapeutic market comprise instruments, software, reagents, and kits. Instruments refer to equipment utilized for precise and accurate execution of activities or experiments. These products find diverse applications in diagnostics and therapeutics and cater to various end-users, including academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, among others.
The exosome diagnostic and therapeutic market consists of revenues earned by entities by providing services such as genomic sequencing, exome sequencing, resequencing, and targeted sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. The exosome diagnostic and therapeutic market also includes sales of exosome-based assays, exosome flow cytometry kits, and protein biomarker detection kits, which are used in providing exosome-based drug delivery services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Exosome Diagnostic and Therapeutic Market Characteristics
3. Exosome Diagnostic and Therapeutic Market Supply Chain Analysis
4. Global Exosome Diagnostic and Therapeutic Market Trends and Strategies
5. Exosome Diagnostic and Therapeutic Market Analysis of End Use Industries
7. Global Exosome Diagnostic and Therapeutic Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Exosome Diagnostic and Therapeutic Total Addressable Market (TAM) Analysis for the Market
9. Exosome Diagnostic and Therapeutic Market Segmentation
10. Exosome Diagnostic and Therapeutic Market Regional and Country Analysis
11. Asia-Pacific Exosome Diagnostic and Therapeutic Market
12. China Exosome Diagnostic and Therapeutic Market
13. India Exosome Diagnostic and Therapeutic Market
14. Japan Exosome Diagnostic and Therapeutic Market
15. Australia Exosome Diagnostic and Therapeutic Market
16. Indonesia Exosome Diagnostic and Therapeutic Market
17. South Korea Exosome Diagnostic and Therapeutic Market
18. Taiwan Exosome Diagnostic and Therapeutic Market
19. South East Asia Exosome Diagnostic and Therapeutic Market
20. Western Europe Exosome Diagnostic and Therapeutic Market
21. UK Exosome Diagnostic and Therapeutic Market
22. Germany Exosome Diagnostic and Therapeutic Market
23. France Exosome Diagnostic and Therapeutic Market
24. Italy Exosome Diagnostic and Therapeutic Market
25. Spain Exosome Diagnostic and Therapeutic Market
26. Eastern Europe Exosome Diagnostic and Therapeutic Market
27. Russia Exosome Diagnostic and Therapeutic Market
28. North America Exosome Diagnostic and Therapeutic Market
29. USA Exosome Diagnostic and Therapeutic Market
30. Canada Exosome Diagnostic and Therapeutic Market
31. South America Exosome Diagnostic and Therapeutic Market
32. Brazil Exosome Diagnostic and Therapeutic Market
33. Middle East Exosome Diagnostic and Therapeutic Market
34. Africa Exosome Diagnostic and Therapeutic Market
36. Exosome Diagnostic and Therapeutic Market Competitive Landscape and Company Profiles
37. Exosome Diagnostic and Therapeutic Market Other Major and Innovative Companies
40. Exosome Diagnostic and Therapeutic Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Exosome Diagnostic And Therapeutic Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses exosome diagnostic and therapeutic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for exosome diagnostic and therapeutic? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The exosome diagnostic and therapeutic market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Instruments; Software; Reagents And Kits2) By Application: Diagnostics; Therapeutic
3) By End User: Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Hospitals And Clinics; Other End Users
Subsegments:
1) By Instruments: Exosome Isolation Systems; Characterization Instruments; Analysis Devices2) By Software: Data Analysis Software; Exosome Profiling Software
3) By Reagents And KITS: Isolation KITS; Characterization Reagents; Assay KITS
Companies Mentioned: Thermo Fisher Scientific Inc.; Miltenyi Biotec GmbH; Malvern Instruments Inc.; System Biosciences LLC; NanoSomix Inc.; Exosome Diagnostics Inc.; Evox Therapeutics Ltd.; ExCoBio Inc.; Codiak BioSciences Inc.; Capricor Therapeutics Inc.; Aethlon Medical Inc.; NX Pharmagen Inc.; Aegle Therapeutic Corporation; Ciloa; Sistemic Inc.; Theoria Science; Mantra Bio Inc.; Lonza Group AG; Bio-Techne Corp.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Exosome Diagnostic and Therapeutic market report include:- Thermo Fisher Scientific Inc.
- Miltenyi Biotec GmbH
- Malvern Instruments Inc.
- System Biosciences LLC
- NanoSomix Inc.
- Exosome Diagnostics Inc.
- Evox Therapeutics Ltd.
- ExCoBio Inc.
- Codiak BioSciences Inc.
- Capricor Therapeutics Inc.
- Aethlon Medical Inc.
- NX Pharmagen Inc.
- Aegle Therapeutic Corporation
- Ciloa
- Sistemic Inc.
- Theoria Science
- Mantra Bio Inc.
- Lonza Group AG
- Bio-Techne Corp.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.77 Billion |
| Forecasted Market Value ( USD | $ 2.07 Billion |
| Compound Annual Growth Rate | 28.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
